1 recruiting, 1 unknown. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA): new trials by email Literature Review of MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) trials Research Report on MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - HCC, Hepatocellular Carcinoma | Unknown | Charite University, Berlin, Germany | 150 | 2022-01-01 | 2022-01-21 |
Carcinoma, Hepatocellular (1) · Cholangitis, Sclerosing (1)
Charite University, Berlin, Germany (1) · Mayo Clinic (1)
Germany (1) · United States (1)